B
Bastiaan E. de Galan
Researcher at Maastricht University
Publications - 107
Citations - 8886
Bastiaan E. de Galan is an academic researcher from Maastricht University. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 20, co-authored 67 publications receiving 7942 citations. Previous affiliations of Bastiaan E. de Galan include Radboud University Nijmegen Medical Centre & Royal Prince Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application
Uffe Søholm,Melanie Broadley,Natalie Zaremba,Patrick M. Divilly,Giesje Nefs,Zeinab Mahmoudi,Bastiaan E. de Galan,Ulrik Pedersen-Bjergaard,Alan Brennan,Daniel Pollard,Rory J. McCrimmon,Stephanie A. Amiel,Christel Hendrieckx,Jane Speight,Pratik Choudhary,Frans Pouwer +15 more
TL;DR: The development and planned psychometric analyses of the Hypo-METRICS app are described and a large-scale, multicountry study including interviews with users and psychometric validation is planned.
Journal ArticleDOI
Hypo‐METRICS: Hypoglycaemia—MEasurement, ThResholds and ImpaCtS—A multi‐country clinical study to define the optimal threshold and duration of sensor‐detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol
Patrick M. Divilly,Natalie Zaremba,Zeinab Mahmoudi,Uffe Søholm,Daniel Pollard,Melanie Broadley,Evertine J. Abbink,Bastiaan E. de Galan,Ulrik Pedersen-Bjergaard,Eric Renard,Mark D. Evans,Jane Speight,Alan Brennan,Rory J. McCrimmon,M. Müllenborn,Simon Heller,Alexander Seibold,Julia K. Mader,Stephanie A. Amiel,Frans Pouwer,Pratik Choudhary +20 more
TL;DR: Hypo‐METRICS is an observational study designed to define the threshold and duration of sensor glucose that provides the optimal sensitivity and specificity for events that people living with diabetes experience as hypoglycaemia.
Journal ArticleDOI
Lactate infusion as therapeutical intervention: a scoping review
TL;DR: In this article , the authors summarized the key data on therapeutic use of intravenous infusion of sodium lactate in humans and showed the potential benefits of therapeutic lactate infusion under certain pathological circumstances, including rather common clinical conditions like traumatic brain injury.
Journal ArticleDOI
Trials of cardiovascular risk factor management in type 2 diabetes.
TL;DR: Recent clinical trial data have cemented the crucial role of BP-lowering and statin treatment for the prevention of cardiovascular events in patients with diabetes, but the uncertainty about intensive glucose control for these outcomes remains.
Journal ArticleDOI
Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Randomized Controlled Trial
TL;DR: Six weeks treatment with exenatide did not improve awareness of hypoglycemia in patients with type 1 diabetes and IAH, and adjunctive treatment with glucagon-like peptide-1 (GLP-1) receptor agonists may reduce glucose variability and improve awareness.